InvestorsHub Logo
Followers 11
Posts 1237
Boards Moderated 0
Alias Born 03/03/2019

Re: None

Thursday, 09/24/2020 2:32:51 PM

Thursday, September 24, 2020 2:32:51 PM

Post# of 436
MediciNova said administering MN-166 with cancer medication oxaliplatin resulted in improvement or stabilization of oxaliplatin-induced neurotoxicity in the majority of participants treated with oxaliplatin.

Half of the study's participants "reported improved symptoms in the acute period and showed improved neurological parameters on clinical assessment with ibudilast treatment," said MediciNova CEO and President Yuichi Iwaki in a statement.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MNOV News